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Background/aim: New treatment regimens for COVID-19, which has threatened the world recently, continue to be investigated.
Although some of the treatments are promising, it is thought to be early to state that there is definitive treatment. Experiences and
treatment protocol studies from treatment centers are still important. The aim of this study is to evaluate factors affecting the treatment
process of the first cases followed in our clinic.
Materials and methods: The consecutive hospitalized patients with COVID-19 pneumonia were analyzed in this retrospective and
cross-sectional study. Data were recorded from the electronic and written files of patients.
Results: Eighty-three patients were evaluated. The median age was 50 ± 15 years. Forty-eight (57.8%) patients had one or more
comorbidities. The most common comorbidity was hypertension. The most common symptom was cough in 58 patients (70%). The
overall mortality was 15%, and 85% of the patients were discharged. The time between the onset of symptoms and hospitalization
was statistically significantly longer in deceased patients (P = 0.039). Age, D-Dimer, troponin, CK, CK-MB, ferritin, procalcitonin,
and neutrophil to lymphocyte ratio were statistically significantly higher in deceased patients than survivor patients. In subgroup
analysis, in the patients receiving azithromycin plus hydroxychloroquine and other antibiotics plus hydroxychloroquine, the duration of
hospitalization was shorter in the azithromycin group (P = 0.027).
Conclusion: Early treatment and early admission to the hospital can be crucial for the better treatment process. Combination therapy
with azithromycin may be preferred in the first treatment choice because it can shorten the length of hospital stay.
Key words: COVID-19, pneumonia, azithromycin, hydroxychloroquine, treatment, mortality, biomarkers

1. Introduction
In December 2019, the Hubei Province in Wuhan, China
reported a pneumonia epidemic of unknown etiology.
A new coronavirus known as severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) was detected in
the throat swab samples of affected patients, and the disease
caused by this virus was named as coronavirus disease
2019 (COVID-19) [1]. As of the first week of March 2020,
cases of COVID-19 started to emerge in Turkey.
Because of the absence of precise management
protocols, new treatment regimens are being investigated
for the management of COVID-19. Some of these
treatments have delivered unfavorable outcomes, whereas
some of them have provided promising results. Although
treatment results are being meticulously presented in
clinical trials, it is considered too early to clearly state the
accuracy of the treatment methods [2]. For this reason,

experiences in the treatment processes coming from
treatment centers and studies of treatment protocols are
still crucial.
In our clinic, which is a tertiary chest diseases training
and research hospital, we have been treating patients
in accordance with the COVID-19 scientific board
recommendations created by the Turkish Ministry of
Health since the beginning of pandemic. Therefore, the
objective of this study is to evaluate the demographic
data, mortality rates, and factors affecting mortality and
treatment processes in the first cases followed up in our
clinic.
2. Material and methods
In this retrospective and cross-sectional study, we
retrospectively analyzed the consecutive hospitalized
patients with COVID-19 pneumonia between March 13,
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2020 and April 15, 2020. This study was conducted in a
tertiary chest diseases training and research hospital that
has been chosen as a pandemic hospital. We recorded age,
sex, contact history, smoking history, and comorbidities
from the electronic and written files of patients. We
also recorded complete blood count, blood chemical
analysis, coagulation testing, liver and renal function tests,
electrolytes, C-reactive protein, procalcitonin, lactate
dehydrogenase, D-Dimer, plasma fibrinogen, and creatine
kinase (CK). In addition, we evaluated the symptoms
of patients, the time from the onset of symptoms to
hospitalization, the need of oxygen inhalation therapy
during hospitalization, noninvasive mechanical ventilation
(NIMV), and intensive care unit (ICU) needs and
treatment regimens. Radiological findings were recorded
by evaluating the thickness of 3 mm axial images with
16-channel multidetector chest computed tomography
(CT). Patients were defined as possible and confirmed
cases according to the case definitions published by the
Ministry of Health [3].
Possible cases comprise:
A: At least one of the signs and symptoms of fever or
acute respiratory disease (cough and respiratory distress),
AND
• The clinical picture cannot be explained by another
cause/disease AND
• Within 14 days before the onset of symptoms, patient
and relatives’ history of being abroad
B: At least one of the signs and symptoms of fever or
acute respiratory disease (cough and respiratory distress),
AND
• Close contact with confirmed COVID-19 case within
14 days prior to the onset of symptoms
C: At least one of the signs and symptoms of fever and
severe acute respiratory infection (cough and respiratory
distress), AND
• The need for hospitalization (SARI*) AND
• The clinical picture cannot be explained by another
cause/disease
*SARI (severe acute respiratory infections: fever, cough
in a patient with acute respiratory infection that developed
in the last 14 days and dyspnea, tachypnea, hypoxemia,
hypotension, and the need for hospitalization due to
changes in diffuse radiological signs and consciousness)
D: Cough or shortness of breath with a sudden onset of
fever and no runny nose
Confirmed cases comprise:
Detection of SARS-CoV-2 in a molecular method in
one of the cases that fits the possible case definition
Oxygen saturation in room air <90%, respiratory
rates ≥30 / min, widespread pneumonic infiltrations on
chest X-rays and/or thorax computed tomography (CT),
or detection of acute organ dysfunction were defined as
“severe disease”.

Hydroxychloroquine 200 mg tablets (2 tablets
twice a day for the first day; 1 tablet twice a day for the
following 4 days) were administered to every inpatient
with COVID-19 pneumonia from the first day of
hospitalization. Third-generation cephalosporin and
quinolone were added as an empiric antibiotic for all
patients. The scientific committee, determined by the
Ministry of Health, regularly updated the management
of COVID-19. In addition to hydroxychloroquine,
azithromycin treatment, depending on the decision of
the treating physician, was recommended on March 25
[3]. From this date, azithromycin tablets (500 mg per
day for the first day; 250 mg per day for the following 4
days) plus hydroxychloroquine were preferred for the
patients of our clinic. With the proposal of the scientific
committee, favipiravir 200 mg tablets (1600 mg loading
dose twice a day; 600 mg twice for the following 4 days)
or lopinavir 200 mg/ritonavir 50 mg tablet (2 tablets twice
a day for 10–14 days) were mostly preferred in patients
with oxygen saturation <90% on room air, respiration rate
over 30 breaths at rest, and rapid clinical and radiological
progression of the disease.
Electrocardiography was performed on all patients and
an electrocardiogram was evaluated before treatment was
started.
Patients who are still undergoing inpatient treatment,
patients with positive influenza test results, and patients
diagnosed with bacterial infection were excluded from the
study.
The ethics committee of our institution approved the
protocol of this study.
2.1. Statistical analysis
We presented continuous measurements as mean ±
standard deviation if they were normally distributed or
median (with minimum and maximum). However, if
continuous measurements are not normally distributed,
then we presented the categorical variables as count (%).
For comparing the groups showing normal distribution, we
used an independent t-test. We used the Mann–Whitney
U test for continuous variables showing the nonnormality
of distribution. Moreover, we used the chi-square test for
testing the relationships between categorical variables. To
evaluate the relationship between symptom duration until
hospital admission and mortality, we determine a cut-off
value for symptom duration by ROC analysis. A P-value of
<0.05 was considered statistically significant in this study.
3. Results
In this study, 83 patients, of whom 41 (49%) were
confirmed cases and 42 (51%) were probable cases, were
evaluated. Sixty (72.2%) patients were male. The median
age of patients was 50 ± 15 years. Fifteen (18%) patients
were smokers, 52 (63%) patients were nonsmokers, and 16
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(19%) patients were former smokers. In total, 48 (57.8%)
patients had one or more comorbidities. The most common
comorbidities were hypertension in 25 (30%) patients,
diabetes mellitus in 12 (14%), coronary heart disease in 10
(12%), and asthma in 8 (10%) patients. The most common
symptom was cough in 58 patients (70%) and fever in 44
(53%) patients, followed by dyspnea in 43 (51%) patients,
fatigue in 30 (36%) patients, myalgia in 20 (24%) patients,
gastrointestinal symptoms including nausea, diarrhea, and
loss of appetite in 20 (24%) patients, sputum in 10 (12%)
patients, sore throat in 7 (8%) patients, headache in 6 (7%)
patients, and hemoptysis in 2 (2.5%) patients. Symptoms
began at a median of 7 days (min: 1–max: 30) before
hospitalization.
The most common radiological localizations were
observed in the right lower (84%) and left lower (80%)
lobes, respectively. Bilateral ground-glass opacity (72%)
was the most common radiological finding on chest CT.
Table 1 presents the radiological features of the patients.
Of 83 patients, 68 (82%) had bilateral involvement and 15
(18%) had unilateral involvement.
There were 38 (46%) severe cases and 45 (54%) mild/
moderate cases. In total, 61 (73%) of the patients needed
oxygen inhalation therapy with nasal cannula or face
mask, 16 (19%) patients were administered NIMV in the
hospital ward, and 19 (22%) patients were administered
invasive mechanical ventilation (IMV) in the ICU. Average
length of stay in ICU was 7 days (min: 1–max: 23). Seven
of the 19 patients who were followed up in the ICU were
successfully weaned and discharged. One patient died
in the hospital ward. The overall mortality was 15%, and
85% of the patients were discharged. The median length
of hospital stay was 8 days (min: 1–max: 29). Unexpected
arrhythmia or cardiac events were not observed during
hospitalization period.
The comparison of clinical and laboratory parameters
of survivor and deceased patients revealed that the time
between the onset of symptoms and hospitalization was
statistically significantly longer in the deceased patients.
Mortality was statistically significantly higher if the time
from the onset of symptoms to the hospital admission was
more than 9 days (≤9 days vs >9 days, P = 0.042, AUC:
2.679, sensitivity: 54%, specificity: 74%, positive predictive
value: 28%, negative predictive value: 90%, and accuracy:
71.1%). Age, D-Dimer, troponin, CK, CK-MB, ferritin,
procalcitonin, and neutrophil to lymphocyte ratio (NLR)
were statistically significantly higher in deceased patients
than the survivor patients. The lymphocyte count was
lower in deceased patients. However, there was no
statistically significant difference in terms of the duration
of hospitalization between survivor and deceased patients
(Table 2).
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Table 1. Radiological features in patients.
Patient number (%)
Lung localization
-Right upper lobe

63 (76)

-Right middle lobe

54 (65)

-Right lower lobe

70 (84)

-Left upper lobe

57 (68)

-Left lower lobe

67 (80)

Distribution
-Central

54 (65)

-Peripheral

76 (91)

-Focal or multifocal

59 (71)

-Diffuse

12 (14)

Image findings
- Bilateral GGO

60 (72)

- Unilateral GGO

12 (14)

-Air bronchogram

28 (33)

-Bronchial vascular enlargement

26 (31)

-Subpleural scarring

19 (23)

-Halo/reverse halo sign

2/20 (2.5/ 25)

-Nodule

8 (9.5)

-Pleural effusion

5 (6)

-Crazy paving

3 (3.6)

-Mediastinal lymph node

2 (2.5)

-Pericardial effusion

2 (2.5)

-Spontaneous pneumothorax

1 (%1.2)

*GGO: ground glass opacity.

Of all patients, 18 received lopinavir/ritonavir and 9
received favipiravir therapy. Five of the patients who took
these drugs died. None of them had received azithromycin
for initiation therapy. No patient received thrombolytic
therapy or immunoglobulin therapy.
We performed subgroup analysis in the patients
receiving azithromycin plus hydroxychloroquine, and
other antibiotics plus hydroxychloroquine, by excluding
patients who were administered favipiravir and lopinavir/
ritonavir. There was no statistically significant difference
between the two groups in terms of age, sex, the time
between the onset of symptoms, D-Dimer, troponin, CK,
CK-MB, ferritin, procalcitonin, and NLR. Additionally,
there was no statistically significant difference between
the two groups in terms of need for ICU and mortality.
However, the duration of hospitalization was shorter in
the group receiving azithromycin than the group receiving
other antibiotics (Table 3).
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Table 2. Comparison of clinical and laboratory parameters of nonsurvivors and survivors.
SURVIVOR (n = 70)

NONSURVIVOR (n = 13)

P

Age (years)

47.7 ± 15

66.8 ± 9.4

<0.001

Presence of comorbidity (n, %)

37 (52.8%)

11 (%84.6)

0.033

Symptom duration before hospitalization (day)

7.4 ± 4.6

11.4 ± 7.3

0.039

Duration of hospitalization (day)

9.5 ± 4.4

7.5 ± 4.5

0.09

Sedimentation rate (mm/hour)

59.7 ± 35.8

60.7 ± 42.8

0.945

D- Dimer (mg/L)

1.35 ± 3.19

1.4 ± 1.17

0.007

Troponin (pg/mL)

3.8 (0.6–67.9)

14.6 (3–7620)

<0.001

CK (U/L)

114 (21–1065)

239.5 (44–1862)

0.039

CK-MB (U/L)

22.55 ± 13.11

36.25 ± 8.14

<0.001

Ferritin (ng/mL)

180 (2–1500)

571.9 (277–1500)

0.008

Fibrinogen (mg/dL)

436.6 ± 128.5

503.75 ± 131.6

0.178

Procalcitonin (mg/L)

0.04 (0.01–1.4)

0.34 (0.02–38.8)

0.001

WBC (10e3/uL)

8.35 ± 3.6

9.32 ± 4.96

0.716

Monocyte (10e3/uL)

0.67 ± 0.39

0.52 ± 0.34

0.092

Eozinophyl (10e3/uL)

0.08 ± 0.13

0.02 ± 0.04

0.095

Lymphocyte (10e3/uL)

1.5 ± 0.73

0.83 ± 0.6

<0.001

Neutrophyl (10e3/uL)

6.03 ± 3.41

7.93 ± 5.05

0.257

NLR (10e3/uL)

4.98 ± 4.5

18.14 ± 23.6

0.006

*WBC: white blood cell; NLR: neutrophil to lymphocyte ratio.

Table 3. Comparison of treatment group with and without azithromycin.
Azithromycin plus
hydroxychloroquine group
(n = 26)

Other antibiotics plus
hydroxychloroquine
group (n = 30)

P

Age (years)

51.65 ± 13.41

46.30 ± 17.07

0.203

Sex (male/female)

18/8

21/9

0.950

Presence of comorbidity (n, %)

16 (61.5 %)

15 (%50)

0.386

Symptom duration before hospitalization (day)

7.96 ± 5.28

7.93 ± 5.42

0.605

Duration of hospitalization (day)

6.68 ± 2.23

8.16 ± 2.56

0.027

Need of ICU (n, %)

5 (19)

6 (20)

0.942

Mortality (n, %)

5 (19)

3 (10)

0.324

Troponin (pg/mL)

4.35 (0.6–113.9)

3.6 (1.5–7620)

0.667

CK (U/L)

121.5 (21–1862)

101 (23–760)

0.782

CK-MB (U/L)

20.20 (7.5–51.70)

19.99 (10.5–98.3)

0.952

D-Dimer (mg/L)

0.62 (0.27 ± 11.47)

0.53 (0.18–6.99)

0.393

Ferritin (ng/mL)

299.5 (37–1500)

155.1 (2–1474)

0.243

Procalcitonin (mg/L)

0.04 (0.01–1.4)

0.04 (0.01–38.86)

0.904

Lymphocyte (10e3/uL)

1.37 (0.32–4.18)

1.39 (0.2–3.71)

0.657

NLR (10e3/uL)

3.05 (0.90–33.69)

4.17 (1.21–87.75)

0.301

*ICU: intensive care unit; CK: creatine kinase; NLR: neutrophil to lymphocyte ratio.
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4. Discussion
COVID-19 is a pandemic that still lacks a definitive and
approved treatment method. For this reason, it is important
to share the predictors and different treatment approaches
from real-life data to reduce mortality and morbidity.
Our study demonstrated that early hospital admission
reduces hospital stay and mortality. To the best of our
knowledge, this is the first report on this issue. In addition,
it has been seen that the combination of azithromycin and
hydroxychloroquine treatment can be effective in reducing
the length of hospital stay.
Death rates reported in the literature vary from 1% to
more than 7% in the COVID-19 pandemic. Overall case
mortality in large scans where the denominator has many
mild or asymptomatic cases across the entire population
were reported as less than 1%, but in the studies with
a much smaller denominator where the hospitalized
patients were evaluated, case death rates were reported
above 5% [4]. Kim et al. did not observe mortality in
their study, which reported the first cases from Korea.
The authors attributed these results to the low number
of elderly and patients with comorbidities. In addition,
some of the patients were asymptomatic in the prodromal
period detected by surveillance test after exposure to virus
[5]. However, mortality rates varied between 13% and 16%
in some studies [6–8]. The mortality was 15% in our clinic.
Our data included the early times of the epidemic, and a
relatively short time frame of the COVID-19 pandemic.
Also, this is a single-center study. Further studies including
a multicenter cohort and longer time of pandemic are
needed. In our patients with mortality, in accordance
with the literature, the presence of comorbidities, NLR,
age, cardiac enzymes, D-dimer, procalcitonin and ferritin
were higher in the deceased group than survivor [9–11].
In addition to the literature, the time from the onset of
symptom to hospitalization was longer in the deceased
group than in the survivors.
From the beginning of the COVID pandemic, we
believed that the patients’ early hospital admission and
early treatment can be beneficial. Indeed, our study results
supported us with lower mortality among the patients
who were admitted earlier. Patients with late admission
were mostly our first patients. With the appearance of first
patients, taking fast precautions and establishing public
spots related to the symptoms and signs of the disease
rapidly increased the patients’ awareness. Early hospital
admission after the onset of symptoms appears to be
effective on mortality. To the best our knowledge, this is
the first report regarding this issue.
Effective and safe treatment strategies still need to be
evaluated to treat the patients before the development
of irreversible respiratory complications, to reduce
the infectious process, and to prevent disease spread.
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Hydroxychloroquine treatment was administered to all the
patients as soon as they were hospitalized without waiting
for PCR results. In addition, in the first cases, thirdgeneration cephalosporin and quinolone groups were
employed for empirical treatment. Later, azithromycin was
added in line with the Turkish scientific committee and
recommendation of the literature.
Hydroxychloroquine accumulates in the cellular
organelles creating acidic environment to inhibit the
replication of different viruses by interfering with
endosome/lysosome trafficking or viral protein maturation
during virions maturation. Azithromycin acts as an
acidotropic lipophilic weak base which modulate the pH
of endosomes and trans-Golgi network, it has a similar
mechanism of action with hydroxychloroquine [12]. A
recently published study reported that it may be beneficial
to combine azithromycin and hydroxychloroquine in the
early reduction of contagiousness and in the treatment of
COVID-19 [13]. However, right after that, another study
was published that claimed contrariwise. The authors of
that study stated they could not find any evidence showing
that this combination therapy provided a strong clinical
response in severe patients who were hospitalized [14]. In
our study including real-life data, we found that the use
of azithromycin in combination with hydroxychloroquine
in a patient group requiring hospitalization may reduce
length of hospital stay, independently from the factors
of comorbidity, age, and sex. This result supported the
study by Gautret et al. [13]. Early preventive measures are
essential to manage this pandemic situation. However,
after contracting the disease, the discharge of patient with
successful outcome needs to be expedited to effectively use
the hospital’s capacity. Therefore, the length of hospital
stay is critical. The organization of all the factors that
positively affect this situation will enable us to manage the
pandemic process in the best way. Therefore, we believe
that azithromycin may be considered in the treatment of
COVID-19 pneumonia.
The most important limitation of our study is the
relatively small sample size. In this study, it was observed
that various risk factors may influence mortality in
COVID-19 pneumonia. More patient groups are required
to evaluate whether these risk factors are independent risk
factors.
In conclusion, early treatment and early admission to
the hospital can be crucial for the better treatment process.
Combination therapy with azithromycin may be preferred
in the first treatment choice because it may shorten the
length of hospital stay. Age, presence of comorbidity,
increased cardiac markers, increased D-Dimer, increased
NLR, high procalcitonin, and ferritin are some factors that
may also be used to predict mortality.
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